Philip D Reilly

US Patent:

20120114637, May 10, 2012

Filed:

May 4, 2010

Appl. No.:

13/265530

Inventors:

Thierry Nivaggioli - Union City CA, US
David A. Weber - Union City CA, US
Philippe JM Dor - Union City CA, US
Philip Reilly - Union City CA, US

Assignee:

SANTEN PHARMACEUTICAL CO., LTD. - Osaka

International Classification:

A61K 31/436
A61K 31/12
A61K 31/192
A61K 31/5377
A61K 31/409
A61K 31/58
A61K 31/4545
A61K 31/675
A61P 27/02
A61K 39/395
A61K 31/4745
A61K 31/404

US Classification:

4241331, 514293, 514679, 514568, 5142335, 514414, 514172, 514318, 514 77, 514291, 5142342, 5142325, 514410

Abstract:

Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.

US Patent:

20170049786, Feb 23, 2017

Filed:

Sep 1, 2016

Appl. No.:

15/254755

Inventors:

- Osaka, JP
David A. WEBER - Danville CA, US
Philippe JM DOR - Kirkland WA, US
Philip REILLY - Portola Valley CA, US

Assignee:

Santen Pharmaceutical Co., Ltd. - Osaka

International Classification:

A61K 31/573
A61K 31/519
A61K 31/506
A61K 9/00
A61K 31/436

Abstract:

Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.